ONGLYZA 2.5 MG
SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) : 2.5 MG · DIN 02375842 · ASTRAZENECA CANADA INC
Health Canada status: MARKETED
What is ONGLYZA?
ONGLYZA 2.5 MG contains SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02375842, held by ASTRAZENECA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Feb-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02375842 |
|---|---|
| Brand name | ONGLYZA |
| Generic / active ingredient | SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) : 2.5 MG |
| Manufacturer | ASTRAZENECA CANADA INC |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BH03 SAXAGLIPTIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Feb-2015 |
What can be used instead?
Other Canadian products sharing ATC code A10BH03 SAXAGLIPTIN. 6 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SAXAGLIPTIN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02507471 |
| APO-SAXAGLIPTIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02507498 |
| ONGLYZA | 5 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | DIN 02333554 |
| SANDOZ SAXAGLIPTIN | 2.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02468603 |
| SANDOZ SAXAGLIPTIN | 5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02468611 |
| PRO-SAXAGLIPTIN | 2.5 MG | TABLET | PRO DOC LIMITEE | APPROVED | DIN 02524333 |
| PRO-SAXAGLIPTIN | 5 MG | TABLET | PRO DOC LIMITEE | APPROVED | DIN 02524341 |
| TEVA-SAXAGLIPTIN | 2.5 MG | TABLET | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02456966 |
| TEVA-SAXAGLIPTIN | 5 MG | TABLET | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02456974 |
Who else supplies SAXAGLIPTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SAXAGLIPTIN appears in 23 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.